0074 Early prognosis prediction: MammaPrint on core-needle biopsies

MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients

“…The MammaPrint test was developed using fresh tumor specimens obtained at the time of surgery. However, more recently, Mayordomo and colleagues showed that sufficient RNA could be isolated from 14-gauge core biopsies to perform array analysis [22,28]. This broadens the clinical applicability of MammaPrint as it eliminates the reliance on surgical specimens, which are often fixed immediately.…”